Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
about
Probing a protein-protein interaction by in vitro evolutionGenome-scale identification of membrane-associated human mRNAs.In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid LibrariesChallenges in Antibody Development against Tn and Sialyl-Tn AntigensThe art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTsDynamics of macrophage trogocytosis of rituximab-coated B cellsA Reverse Binding Motif That Contributes to Specific Protease Inhibition by AntibodiesEngineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesSingle domain antibodies: promising experimental and therapeutic tools in infection and immunityHuman antibody-Fc receptor interactions illuminated by crystal structuresGeneration of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytesVH-VL orientation prediction for antibody humanization candidate selection: A case study.MoFvAb: Modeling the Fv region of antibodies.An antibody-recruiting small molecule that targets HIV gp120.Ultrasonic storage modulus as a novel parameter for analyzing protein-protein interactions in high protein concentration solutions: correlation with static and dynamic light scattering measurements.A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces.A general method for greatly improving the affinity of antibodies by using combinatorial librariesIdentification of a polymeric Ig receptor binding phage-displayed peptide that exploits epithelial transcytosis without dimeric IgA competition.Differential screening of phage-ab libraries by oligonucleotide microarray technology.A yeast display immunoprecipitation method for efficient isolation and characterization of antigens.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptorMolecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesComparative Membranome expression analysis in primary tumors and derived cell lines.A non-chromatographic method for the purification of a bivalently active monoclonal IgG antibody from biological fluidsHuman immune response to a plague vaccine comprising recombinant F1 and V antigens.Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia.Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system.Engineered protein A ligands, derived from a histidine-scanning library, facilitate the affinity purification of IgG under mild acidic conditions.An innovative approach for the characterization of the isoforms of a monoclonal antibody productOverview on the use of therapeutic antibodies in drug discovery.Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.Autoimmunity contributes to nociceptive sensitization in a mouse model of complex regional pain syndrome.Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.The changing role of pathology in breast cancer diagnosis and treatment.Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei
P2860
Q24546265-8E79A75D-0EDD-4D5B-A1D2-6A8EE8D4D2BFQ25256725-FE29386C-8C40-4144-AA7F-25B81EE12C03Q26782129-EBF14D5A-D9E6-4C0E-A2DB-52492545A7C1Q26798183-9D5C6E3A-7F5D-4386-B93A-45CB4E1A9AD8Q26991574-125B525E-C121-4065-97CF-74D3D0BD2D47Q27314806-F51D2531-0717-4D4C-806C-ACE1E3458094Q27676066-2CC01FE8-8A2D-41E2-84DD-8B8CEF89CB82Q27678516-A8F808A3-8FDE-4AFC-B07D-5FB3AA807903Q27690917-C47C86AF-5169-4124-BE18-BCD47D7376ECQ28069362-9A020453-4AE2-4591-B7FB-2B187E283466Q28248678-9A7DB9D5-10E2-47CC-B9C9-B9BD812AA5C3Q28252414-91752AC1-FD3B-40F6-B36F-D1309FB1B997Q30352589-487417D7-2DB8-4B65-8592-3839F3F93F72Q30368433-CB69CDA9-0412-4F4A-BC99-BE4E28E56F04Q30376735-B37DCF3F-ED1F-4AD5-82E3-F0E5F1E4A197Q30381757-FCE24E7B-3D17-4340-8AC1-534A23832042Q30499156-39E4130E-48A7-47C5-A241-0D5604C58392Q30987126-FCF2218A-BEB0-4BBB-A8DE-D79CAC122322Q33216580-CF7C03BF-597F-4E80-B9F1-B444E41D5871Q33232094-7C5E0426-D1CE-49CB-AC86-1C6B1B82E978Q33317276-4967AE61-CD0B-4A2B-AE51-8F4951D05FBCQ33388079-8C90C7A8-4762-4E0B-AC91-FDA44240A279Q33573587-259670A7-66D5-4A07-826F-281D9BD6EDFAQ33629320-81F308BD-447D-40DD-94A0-843363CC9F0EQ33644331-436F860A-E8D7-42E2-8496-50DDB40E1F7EQ33752932-810FC84C-0444-4F81-A947-9B1D10D1DF72Q33788286-B8EF0E9A-870A-4AC3-BEB8-BF6D1F489134Q33809544-0783D02B-3CB7-4F76-B3FF-9C1C89D79A40Q33900390-069B91ED-8CCB-443B-BEEC-43A84027347CQ33936317-27BFFB19-22F5-41F0-9BB1-24C99C77EF86Q34084985-E3F2E3E1-F481-4942-9F1E-E7A193C1309DQ34147273-B0F3D3A4-FA69-48BB-8B8A-9911878503CCQ34232310-BEE36F88-F3E6-48B3-9ABB-1558111F2539Q34240076-9BB2C83E-1EF3-45FE-BE86-4E971AC8C31DQ34301659-CD172589-B819-41FF-AA95-7DCE58890A1EQ34568391-A419B8DF-9204-4069-9F11-B161B10E9649Q34614091-2B9E961C-AB89-4FEB-8340-970229B31CD7Q34983092-0062B4CA-0BE0-46F7-8F7E-75E468D56E6CQ35082260-24CC0F0C-5F2F-4DFA-893E-2BD762D0FC7CQ35116418-AAE13CE4-7349-4A29-B579-A377D3BA000B
P2860
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@ast
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@en
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@nl
type
label
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@ast
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@en
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@nl
prefLabel
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@ast
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@en
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@nl
P356
P1476
Therapeutic antibodies for human diseases at the dawn of the twenty-first century.
@en
P2093
Ole Henrik Brekke
P2888
P356
10.1038/NRD984
P577
2003-01-01T00:00:00Z